An extended release oral dosage form for highly soluble and highly permeable pharmaceutically active PARP inhibitors. The invention relates to the extended release oral dosage form comprising 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide (veliparib) and a gel-forming polymer.